Emma N Rizen1, Alexandria T Phan2,3. 1. Phan & Associates LLC, 3730 Kirby Drive, Suite 1200, Houston, TX, 77098, USA. 2. University of Texas Health Science Center at Tyler, Tyler, USA. atphanmd@gmail.com. 3. Phan & Associates LLC, 3730 Kirby Drive, Suite 1200, Houston, TX, 77098, USA. atphanmd@gmail.com.
Abstract
PURPOSE OF REVIEW: The field of neuroendocrine oncology has changed much since the time of Oberndorfer first described and coined the term carcinoid. The purpose of this review is to summarize recent findings and highlight clinically relevant updates in the management of NENs, particularly those that are practice changing. RECENT FINDINGS: Neuroendocrine tumors (NETs) have replaced carcinoid tumor, for the most part. The classification of neuroendocrine neoplasms (NENs) improved, and the epidemiological understanding of this disease group also expanded with global collaborations and maturation of large tumor registries. Clarity in the utility of some NET biomarkers continues to be evolving. Knowledge of molecular drivers of tumorigenesis increases, and scientific/technological advancements lead the way to multiple drug approvals for the treatment of advanced NETs. The incidence and prevalence of NENs continue to increase, and patients are living longer. Better understanding of molecular drivers and further understanding of the role of immunotherapy in NENs will further elevate the level of care and transform care for all patients with NENs.
PURPOSE OF REVIEW: The field of neuroendocrine oncology has changed much since the time of Oberndorfer first described and coined the term carcinoid. The purpose of this review is to summarize recent findings and highlight clinically relevant updates in the management of NENs, particularly those that are practice changing. RECENT FINDINGS: Neuroendocrine tumors (NETs) have replaced carcinoid tumor, for the most part. The classification of neuroendocrine neoplasms (NENs) improved, and the epidemiological understanding of this disease group also expanded with global collaborations and maturation of large tumor registries. Clarity in the utility of some NET biomarkers continues to be evolving. Knowledge of molecular drivers of tumorigenesis increases, and scientific/technological advancements lead the way to multiple drug approvals for the treatment of advanced NETs. The incidence and prevalence of NENs continue to increase, and patients are living longer. Better understanding of molecular drivers and further understanding of the role of immunotherapy in NENs will further elevate the level of care and transform care for all patients with NENs.
Authors: Janet L Cunningham; Teresita Díaz de Ståhl; Tobias Sjöblom; Gunnar Westin; Jan P Dumanski; Eva T Janson Journal: Genes Chromosomes Cancer Date: 2011-02 Impact factor: 5.006
Authors: Anna Karpathakis; Harpreet Dibra; Chistodoulos Pipinikas; Andrew Feber; Tiffany Morris; Joshua Francis; Dahmane Oukrif; Dalvinder Mandair; Marinos Pericleous; Mullan Mohmaduvesh; Stefano Serra; Olagunju Ogunbiyi; Marco Novelli; TuVinh Luong; Sylvia L Asa; Matthew Kulke; Christos Toumpanakis; Tim Meyer; Martyn Caplin; Matthew Meyerson; Stephan Beck; Christina Thirlwell Journal: Clin Cancer Res Date: 2015-07-13 Impact factor: 12.531
Authors: Cornelius J Fernandez; Mayuri Agarwal; Biju Pottakkat; Nisha Nigil Haroon; Annu Susan George; Joseph M Pappachan Journal: World J Gastrointest Surg Date: 2021-03-27
Authors: Lauren Fishbein; Jaydira Del Rivero; Tobias Else; James R Howe; Sylvia L Asa; Debbie L Cohen; Patricia L M Dahia; Douglas L Fraker; Karyn A Goodman; Thomas A Hope; Pamela L Kunz; Kimberly Perez; Nancy D Perrier; Daniel A Pryma; Mabel Ryder; Aaron R Sasson; Michael C Soulen; Camilo Jimenez Journal: Pancreas Date: 2021-04-01 Impact factor: 3.327